data access
Trust and transparency in Pharma & healthcare: impact of the COVID-19 pandemic
While it is obvious that trust in life science and healthcare companies is suboptimal, exactly how to improve the public’s trust is unclear...
Policy and public health: all the decisions we can’t see
January was a bad month for healthcare in China
GSK to reverse ‘no KOLs’ policy, admitting it has hit marketing
Company seeking to revive lacklustre marketing performance
Transparency and accountability: tackling opacity and blame head-on
Let’s be honest, big pharma lacks trust and many love to hate it. Faceless corporations tainted by past own-goals, profiteering, cherry-picked data and spun claims - so goes the lazy...
Is trust in healthcare improving?
Edelman’s Annual Trust Barometer for 2017 painted a sobering picture of trust around the globe with a collapse in trust in all four of the major institutions studied - business,...
UCB collaborates with UK’s Medical Research Council
The partners will support researchers developing antibody-based therapeutics
Focus on value: A prescription for pharma
The pricing debate demands a common language to be developed
Nearly half of HCPs refuse to disclose pharma payments
Industry data shows firms spent £363m on working with healthcare professionals
Medical Research Council launches disease compounds research library
Teams up with AZ, GSK, Janssen, Pfizer, Takeda and UCB
Germany’s IQWIG ‘perplexed’ by EMA’s adaptive pathways plan
Reliance on real-world evidence questioned
Tracking comms trends: tackling reputational issues head on
From multi-disciplinary teamwork to pharma’s reputation, value and access to global briefs, our contributors tackle some of the key topics in communications today
Leveraging HCP transparency insights to drive future customer investments
EFPIA’s disclosure requirements present an opportunity to assess strategy and effectiveness